Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
March 28, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
December 14, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
November 02, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
October 25, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
October 09, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
October 06, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
June 30, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
June 26, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
June 15, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Announces Pricing of Public Offering of Common Stock
May 03, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 03, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 27, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
March 14, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
March 09, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
February 02, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
January 31, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 08, 2022
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
November 03, 2022
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
July 26, 2022
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RPHM
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.